49. Systemic lupus erythematosus Clinical trials / Disease details

Clinical trials : 946 / Drugs : 722 - (DrugBank : 186) / Drug target genes : 117 - Drug target pathways : 199

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02070978 (ClinicalTrials.gov)	July 29, 2014	21/2/2014	Long-term Safety and Tolerability of Atacicept (Long-term Follow-Up of Participant Who Participated in ADDRESS II)	A Phase IIb, Multi-Center, Long-Term Extension Trial to Evaluate the Safety and Tolerability of Atacicept in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed Protocol EMR-700461-023 (ADDRESS II)	Lupus Erythematosus, Systemic	Drug: Atacicept 75 mg;Drug: Atacicept 150 mg	EMD Serono	NULL	Terminated	18 Years	N/A	All	253	Phase 2	United States;Argentina;Brazil;Bulgaria;Chile;Czechia;Germany;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Russian Federation;South Africa;Spain;United Kingdom
2	NCT00624338 (ClinicalTrials.gov)	January 2008	15/2/2008	Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)	A Randomised, Double-blind, Placebo Controlled, Multicentre Prospective Dose-finding Phase II/III Study With Atacicept Given Subcutaneously to Subjects Having Recently Experienced a Flare of Systemic Lupus Erythematosus (SLE)	Lupus Erythematosus, Systemic	Drug: Atacicept 75 mg;Drug: Atacicept 150 mg;Other: Placebo Comparator	EMD Serono	Merck KGaA	Completed	16 Years	N/A	All	461	Phase 2/Phase 3	United States;Argentina;Australia;Austria;Bulgaria;Croatia;Czech Republic;France;Germany;Greece;India;Israel;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;Ukraine;United Kingdom